clinical trial · NCT06788912
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
Merck Sharp & Dohme LLC·phase2·recruiting·n = 60
Lung Neoplasm MalignantPembrolizumab (neoadjuvant)CisplatinGemcitabinePemetrexedSacituzumab tirumotecanH1 receptor antagonistH2 receptor antagonistAcetaminophen (or equivalent)
brief summary
The main goals are after treatment given before surgery, to measure the number of people who have no signs of cancer cells in tumors and lymph nodes removed during surgery; and to learn about whether the cancer gets smaller or goes away by measuring the number of people with a certain number of living cancer cells in the tumor removed during surgery.
started
Mar 20, 2025
primary completion
Feb 6, 2032
completion
Feb 6, 2032
last updated
Jun 1, 2026
official title
KEYMAKER-U01 Substudy 01E: A Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With or Without Chemotherapy in Combination With Pembrolizumab in Treatment of Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol